 |
|
|
| |
A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer and HBV patient population
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Edward Gane1, Christian Schwabe1, Bruce D. Given2, Thomas Schluep2, James Hamilton2, Ching-Lung Lai3, Stephen A. Locarnini4, Johnson YN Lau3, 5, Carlo Ferrari6, Robert G. Gish7,8
1 Auckland Clinical Studies, Auckland, New Zealand, 2 Arrowhead Research Corporation, Pasadena, CA, USA, 3 The Chinese University of Hong Kong, Hong
Kong, China, 4 Victorian Infectious Diseases Reference Laboratory, Victoria, Australia, 5 Hong Kong Polytechnic University, Hong Kong, China 6, University of
Parma, Parma, Italy 7, Stanford University, Palo Alto, CA, USA, 8 Hepatitis B Foundation, Doylestown, PA, USA
|
| |
|
|
|
|
|
